To compare the clinical efficacy and safety of labetalol injection and nifedipine controlled-release tablets combined with magnesium sulfate injection and calcium carbonate D3 tablets in the treatment of preeclampsia.

The patients with preeclampsia who were hospitalized in the obstetrics department of our hospital were included as the research objects, and the patients were divided into group A, group B and group C according to the medication plan. Group A was treated with labetalol hydrochloride injection 100-200 mg, intravenous drip, 1.5-3.5 mg per minute, once a day combined with 25% magnesium sulfate injection 60 mL, intravenous drip, 1.55-2.0 g per hour, 25 g per day and calcium carbonate D3 tablets, take orally, 300 mg each time, twice a day; Group B was treated with nifedipine controlled-release tablets orally, 30 mg each time, once a day, and the administration methods of magnesium sulfate injection, calcium carbonate D3 tablets were the same as those in group A; Group C was treated with labetalol hydrochloride injection, nifedipine controlled-release tablets, magnesium sulfate injection and calcium carbonate D3 tablets, and the administration methods of them were the same as those in group A and group B. The clinical efficacy, blood pressure condition, heart and kidney function, psychological status, fetal hemodynamics, maternal and pregnancy outcome of patients in 3 groups were compared, and the safety was evaluated.

A total of 170 patients were enrolled, 90 patients in group A, 39 patiets in group B and 41 patients in group C. After treatment, the total effective rates of group A, Group B and Group C were 58.89% (53 cases/90 cases), 53.85% (21 cases / 39 cases) and 85.37% (35 cases / 41 cases), respectively, and the blood pressure recovery time were 3.00 (3.00,5.00), 3.00 (3.00,5.00), and 7.00 (3.00,9.00) d, respectively. The total effective rate of group C was statistically significantly higher than that of group A and group B (all P<0.05), and the recovery time of blood pressure was statistically significantly shorter than that of group A and group B (all P<0.05). After treatment, the systolic blood pressures of group A, group B and group C were (145.60±5.15), (143.72±4.86) and (137.24±5.07) mmHg, respectively; the diastolic blood pressures were (97.83±6.56), (96.72±7.00) and (86.80±4.87) mmHg, respectively; Hamilton anxiety scale scores were 15.00 (13.00,17.00), 15.00 (13.50,17.50) and 12.00 (11.00,14.00) points, respectively; the Hamilton depression scale scores were 14.00 (12.00,15.00), 14.00 (12.00,15.00) and 10.00 (9.00,12.00) points, respectively; and the above indicators in group C were all lower than those of group A and group B (all P<0.05). After treatment, the B-type natriuretic peptide levels in group A, group B and group C were 35.00 (21.00,56.00), 42.00 (22.50,90.50) and 24.00 (13.00,60.00) pg·L^-1, respectively; the the urinary protein levels were 0.35 (0.14,0.57), 0.24 (0.15, 0.39) and 0.14 (0.06,0.34) g, respectively; and the B-type natriuretic peptide level of group C was statistically significantly lower than that of group B (P<0.05), and the urinary protein level was statistically significantly lower than that of group A (P<0.05). After treatment, the diastolic flow velocity ratio in group A, Group B and group C were 2.15 (1.92, 2.24), 2.04 (1.86, 2.23), 2.16 (2.02, 2.25), respectively; the flow resistance index were 0.53 (0.48, 0.55), 0.51 (0.46, 0.56), 0.54 (0.51, 0.58), respectively; the flow pulse index were 0.77 (0.66, 0.83), 0.69 (0.63, 0.80), 0.77 (0.67, 0.81), respectively; the incidence rates of adverse drug reactions were 13.33% (12 cases / 90 cases), 12.82% (5 cases / 39 cases) and 12.20% (5 cases / 41 cases), respectively; and there were no statistically significant differences in the above indicators and pregnancy outcome among the three groups (all P>0.05).

The therapy with labetalol, nifedipine, magnesium sulfate and calcium in PE is better, which can improve the blood pressure level, psychological status, heart and kidney function, maternal and infant outcomes, regulate fetal hemodynamics, and will not cause serious adverse reactions.